Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avdoralimab - Innate Pharma

Next Previous
Drug Profile

Avdoralimab - Innate Pharma

Alternative Names: Anti-C5aR-215; IPH-5401; NN-8210; NNC-0215-0384

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer AstraZeneca; Innate Pharma; Novo Nordisk
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bullous pemphigoid; Chronic urticaria; COVID-19 pneumonia; Liver cancer; Non-small cell lung cancer; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 31 Mar 2024 Centre Hospitalier Universitaire de Nice completes a phase II trial in Bullous pemphigoid (In adults, In the elderly) in France (SC) (NCT04563923) (EudraCT2020-002912-34)
  • 23 Mar 2023 Avdoralimab - Innate Pharma is available for licensing as of 23 Mar 2023
  • 23 Mar 2023 Discontinued - Phase-II for Bullous pemphigoid (In the elderly, In adults) in France (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top